Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

3372 - Impact on OS and PFS of 2nd and 3rd generation TKI in EGFR mt+ and ALK+ pts: Results of the NOWEL network

Date

09 Sep 2017

Session

Poster display session

Presenters

Julia Roeper

Citation

Annals of Oncology (2017) 28 (suppl_5): v460-v496. 10.1093/annonc/mdx380

Authors

J. Roeper1, A. Lueers1, M. Netchaeva1, M. Falk2, C. Hallas2, M. Tiemann2, N. Neemann3, L. Heukamp3, C. Wesseler4, G.H. Wiest4, D. Ukena5, S. Sackmann5, F. Griesinger1

Author affiliations

  • 1 Department Of Internal Medicine-oncology, Pius Hospital Oldenburg, University of Oldenburg, 26121 - Oldenburg/DE
  • 2 Department Of Hematopathology, Hematopathology Hamburg, 22547 - Hamburg/DE
  • 3 Department Of Pathology, NEO New Oncology, Köln/DE
  • 4 Department Of Oncology, Asklepios Klinik Harburg, 21075 - Hamburg/DE
  • 5 Department Of Oncology, Klinikum Bremen Ost, Bremen/DE
More

Resources

Abstract 3372

Background

Clinical research data shows that early mutation testing for pts with NSCLC stage IV could lead to an effective choice of therapy for pts with proven mutations. Targeted therapies achieve a higher ORR, OS, PFS and a better quality of life than chemotherapy in mt+ pts. With the advent of 2nd and 3rd generation TKÍs effective in 1st generation TKI resistant tumors, we wanted to study the impact of these drugs on the outcome of pts in a real life setting.

Methods

1381 pts from three cancer centers diagnosed with non-squamous cell NSCLC stage IV (UICC 7) were examined. Methods for the mutation testing was performed according to the German Oncopedia guidelines using either Sanger Sequencing or COBAS® or Next Generation Sequencing (hybrid capture NGS, New Oncology Cologne).

Results

879/1381 (64%) consecutive pts with non-squamous cell NSCLC from three cancer centers were studied for the presence of tumor mutations, especially for EGFR and ALK mt+. The EGFR mt+ rate was 16.6% (141/847), and the ALK-translocation rate 3.8% (24/635). Median OS in EGFR mt+ pts was 28 (n = 79) vs. 28 (n = 38) vs. 16 (n = 14) months respectively (center 1 vs. center 2 vs. center 3). Median OS in ALK mt+ pts was 24 months (n = 17) in center 1 and 11 months (n = 5) in center 2 (p 

Conclusions

Small differences in OS were observed, depending on the treatment centers, but the use of multiple EGFR and ALK-I impacted highly significantly on the outcome of pts with EGFR and ALK mt+ in a real life setting.

Clinical trial identification

Legal entity responsible for the study

Faculty 6 University of Oldenburg

Funding

None

Disclosure

M. Falk: Member of Advisory board: Boehringer Ingelheim, Pfizer Professional fee: Roche, Astra Zeneca, Boehringer Ingelheim. M. Tiemann: Member of Advisory board: Novartis, Boehringer, Roche, Astra Zeneca Professional fee: Novartis, Boehringer, Roche, Astra Zeneca Corporate-sponsored Research: Novartis. L. Heukamp: Member of advisory board: BMS, Boehringer, Roche Diaganostics, Novartis F. Griesinger: Advisory board/Scientific Support/Professional fee: Ariad, Astra-Zeneca, Boehringer-Ingelheim, Bristol-Myer-Squibb, Celgene, Clovis, Lilly, Merck-Sharp-Dome, Novartis, Pfizer, Roche. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.